| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.046 | 0.4 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.05 | 0.4 |
| mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.4 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.096 | 0.4 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |